These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 9412541

  • 1. Protective effects of carvedilol in the myocardium.
    Feuerstein GZ, Bril A, Ruffolo RR.
    Am J Cardiol; 1997 Dec 04; 80(11A):41L-45L. PubMed ID: 9412541
    [Abstract] [Full Text] [Related]

  • 2. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure.
    Ruffolo RR, Feuerstein GZ.
    Cardiovasc Drugs Ther; 1997 May 04; 11 Suppl 1():247-56. PubMed ID: 9211017
    [Abstract] [Full Text] [Related]

  • 3. Recent observations with beta-adrenoceptor blockade. Beneficial effects in hypertension and heart failure.
    Ruffolo RR, Feuerstein GZ, Ohlstein EH.
    Am J Hypertens; 1998 Jan 04; 11(1 Pt 2):9S-14S. PubMed ID: 9503101
    [Abstract] [Full Text] [Related]

  • 4. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection.
    Feuerstein GZ, Ruffolo RR.
    Eur Heart J; 1996 Apr 04; 17 Suppl B():24-9. PubMed ID: 8733068
    [Abstract] [Full Text] [Related]

  • 5. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity.
    Feuerstein GZ, Yue TL, Cheng HY, Ruffolo RR.
    J Hypertens Suppl; 1993 Jun 04; 11(4):S41-8. PubMed ID: 8104241
    [Abstract] [Full Text] [Related]

  • 6. Pharmacodynamic profile of carvedilol.
    van Zwieten PA.
    Cardiology; 1993 Jun 04; 82 Suppl 3():19-23. PubMed ID: 8106159
    [Abstract] [Full Text] [Related]

  • 7. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure.
    Ruffolo RR, Feuerstein GZ.
    J Cardiovasc Pharmacol; 1998 Jun 04; 32 Suppl 1():S22-30. PubMed ID: 9731692
    [Abstract] [Full Text] [Related]

  • 8. Beta-blockers in congestive heart failure: the pharmacology of carvedilol, a vasodilating beta-blocker and antioxidant, and its therapeutic utility in congestive heart failure.
    Feuerstein G, Ruffolo RR.
    Adv Pharmacol; 1998 Jun 04; 42():611-5. PubMed ID: 9327976
    [No Abstract] [Full Text] [Related]

  • 9. Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol.
    Feuerstein G, Yue TL, Ma X, Ruffolo RR.
    Prog Cardiovasc Dis; 1998 Jun 04; 41(1 Suppl 1):17-24. PubMed ID: 9715819
    [Abstract] [Full Text] [Related]

  • 10. Effects of carvedilol on left ventricular function and arrhythmias during repeated short-time myocardial ischemia in experimental pigs.
    Höher M, Friedrich M, Sommer T, Marten A, Ehmer B, Hombach V, Hirche H.
    Z Kardiol; 1989 Jun 04; 78 Suppl 3():7-15. PubMed ID: 2573214
    [Abstract] [Full Text] [Related]

  • 11. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger.
    Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, Lysko KA, Davis LL, Feuerstein G.
    J Pharmacol Exp Ther; 1992 Oct 04; 263(1):92-8. PubMed ID: 1357162
    [Abstract] [Full Text] [Related]

  • 12. Vasodilatory action of carvedilol.
    Sponer G, Strein K, Bartsch W, Müller-Beckmann B.
    J Cardiovasc Pharmacol; 1992 Oct 04; 19 Suppl 1():S5-11. PubMed ID: 1378150
    [Abstract] [Full Text] [Related]

  • 13. Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential.
    Cheng J, Kamiya K, Kodama I.
    Cardiovasc Drug Rev; 2001 Oct 04; 19(2):152-71. PubMed ID: 11484068
    [Abstract] [Full Text] [Related]

  • 14. Electrophysiologic effects of carvedilol: is carvedilol an antiarrhythmic agent?
    El-Sherif N, Turitto G.
    Pacing Clin Electrophysiol; 2005 Sep 04; 28(9):985-90. PubMed ID: 16176541
    [Abstract] [Full Text] [Related]

  • 15. Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers.
    Hanada K, Asari K, Saito M, Kawana J, Mita M, Ogata H.
    Eur J Pharmacol; 2008 Jul 28; 589(1-3):194-200. PubMed ID: 18534575
    [Abstract] [Full Text] [Related]

  • 16. Pharmacology of carvedilol.
    Dulin B, Abraham WT.
    Am J Cardiol; 2004 May 06; 93(9A):3B-6B. PubMed ID: 15144929
    [Abstract] [Full Text] [Related]

  • 17. Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model.
    Feuerstein G, Liu GL, Yue TL, Cheng HY, Hieble JP, Arch JR, Ruffolo RR, Ma XL.
    Eur J Pharmacol; 1998 Jun 26; 351(3):341-50. PubMed ID: 9721026
    [Abstract] [Full Text] [Related]

  • 18. Carvedilol blockade of alpha1- and beta-adrenoceptor induced inotropic responses in rats with congestive heart failure.
    Qvigstad E, Sjaastad I, Bøkenes J, Schiander I, Solberg L, Sejersted OM, Osnes JB, Skomedal T.
    Eur J Pharmacol; 2005 May 23; 516(1):51-9. PubMed ID: 15916756
    [Abstract] [Full Text] [Related]

  • 19. Sympathetic activation and the role of beta-blockers in chronic heart failure.
    Krum H.
    Aust N Z J Med; 1999 Jun 23; 29(3):418-27. PubMed ID: 10868514
    [Abstract] [Full Text] [Related]

  • 20. Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.
    Dunn CJ, Lea AP, Wagstaff AJ.
    Drugs; 1997 Jul 23; 54(1):161-85. PubMed ID: 9211087
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.